Amgen's Aranesp Achieves Primary Aim In MDS Trial
This article was originally published in Scrip
Executive Summary
Amgen Inc's legacy product Aranesp (darbepoetin alfa) has met its primary goal of reducing the incidence of red blood cell transfusions in anaemic patients suffering from myelodysplastic syndrome (MDS) in a Phase III trial dubbed ARCADE, results of which will be presented at a future unspecified medical conference, the California-based company said in a statement Feb. 16.